To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Europe | European ＆ international partnerships | Metabolomics | Diseases | Diagnosis
The pan-European research project MICROB-PREDICT aims to better understand the role of the human microbiome in the pathogenesis and evolution of cirrhosis and to imagine future personalized therapeutic strategies and diagnostic tools.
Every year, 1.2 million people worldwide die from complications of liver cirrhosis (decompensation, acute or chronic liver failure). The main causes of the disease are alcoholism and viral infections (hepatitis), with certain factors such as diabetes and obesity worsening the prognosis. Among the recent advances in the understanding of the disease, the role of the intestinal microbiota (formerly known as gut flora) in the pathogenesis and progression of the disease is of great interest. There are quantitative and qualitative differences in its composition between people with cirrhosis and healthy people, differences that are notably linked to the migration of certain microorganisms from or to other microbiota in the body (salivary microbiota, circulatory microbiota...). The study of the microbiota, or rather the microbiome, should therefore make it possible, on the one hand, to predict and prevent the occurrence and/or aggravation of cirrhosis and, on the other hand, to propose adapted and personalized therapeutic solutions.
This is the challenge taken up by the MICROB-PREDICT consortium, funded by the European Union for six years. This pan-European research project will integrate data from some 10,000 patients, previously collected in other large-scale studies, constituting a database of more than 100,000 data points, including stool, blood, saliva, mucous membrane and urine samples taken throughout the course of the disease. The consortium is particularly interested in identifying biomarkers of different stages of the disease and exploiting them to develop tests for use by physicians or patients, such as emergency diagnostic tests (Point Of Care (POC)) tests.
Contact Joliot Institute: Christophe Junot (firstname.lastname@example.org)
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.